146 related articles for article (PubMed ID: 32069833)
1. Biphasic Mathematical Model of Cell-Drug Interaction That Separates Target-Specific and Off-Target Inhibition and Suggests Potent Targeted Drug Combinations for Multi-Driver Colorectal Cancer Cells.
Shen J; Li L; Yang T; Cohen PS; Sun G
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32069833
[TBL] [Abstract][Full Text] [Related]
2. Application of a Biphasic Mathematical Model of Cancer Cell Drug Response for Formulating Potent and Synergistic Targeted Drug Combinations to Triple Negative Breast Cancer Cells.
Shen J; Li L; Howlett NG; Cohen PS; Sun G
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32349331
[TBL] [Abstract][Full Text] [Related]
3. Drug Sensitivity Screening and Targeted Pathway Analysis Reveal a Multi-Driver Proliferative Mechanism and Suggest a Strategy of Combination Targeted Therapy for Colorectal Cancer Cells.
Shen J; Li L; Yang T; Cheng N; Sun G
Molecules; 2019 Feb; 24(3):. PubMed ID: 30754629
[TBL] [Abstract][Full Text] [Related]
4. Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells.
Ku GC; Chapdelaine AG; Ayrapetov MK; Sun G
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011019
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
7. Targeted drug combination therapy design based on driver genes.
Zsákai L; Sipos A; Dobos J; Erős D; Szántai-Kis C; Bánhegyi P; Pató J; Őrfi L; Matula Z; Mikala G; Kéri G; Peták I; Vályi-Nagy I
Oncotarget; 2019 Sep; 10(51):5255-5266. PubMed ID: 31523388
[TBL] [Abstract][Full Text] [Related]
8. A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs.
Pal R; Berlow N
Pac Symp Biocomput; 2012; ():351-62. PubMed ID: 22174290
[TBL] [Abstract][Full Text] [Related]
9. Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology.
Lim H; He D; Qiu Y; Krawczuk P; Sun X; Xie L
PLoS Comput Biol; 2019 Jun; 15(6):e1006619. PubMed ID: 31206508
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
11. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
Sen K; Banerjee S; Mandal M
Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
[TBL] [Abstract][Full Text] [Related]
12. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
Haltia UM; Andersson N; Yadav B; Färkkilä A; Kulesskiy E; Kankainen M; Tang J; Bützow R; Riska A; Leminen A; Heikinheimo M; Kallioniemi O; Unkila-Kallio L; Wennerberg K; Aittokallio T; Anttonen M
Gynecol Oncol; 2017 Mar; 144(3):621-630. PubMed ID: 28104295
[TBL] [Abstract][Full Text] [Related]
13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
14. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
15. Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs.
Uitdehaag JC; de Roos JA; van Doornmalen AM; Prinsen MB; Spijkers-Hagelstein JA; de Vetter JR; de Man J; Buijsman RC; Zaman GJ
PLoS One; 2015; 10(5):e0125021. PubMed ID: 26018524
[TBL] [Abstract][Full Text] [Related]
16. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C
BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709
[TBL] [Abstract][Full Text] [Related]
17. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
18. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
19. In silico-in vitro discovery of untargeted kinase-inhibitor interactions from kinase-targeted therapies: A case study on the cancer MAPK signaling pathway.
Meng L; Huang Z
Comput Biol Chem; 2018 Aug; 75():196-204. PubMed ID: 29803964
[TBL] [Abstract][Full Text] [Related]
20. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.
Ravikumar B; Aittokallio T
Expert Opin Drug Discov; 2018 Feb; 13(2):179-192. PubMed ID: 29233023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
